1. Home
  2. DX vs HRMY Comparison

DX vs HRMY Comparison

Compare DX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynex Capital Inc.

DX

Dynex Capital Inc.

N/A

Current Price

$9.93

Market Cap

2.6B

Sector

Real Estate

ML Signal

N/A

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

N/A

Current Price

$32.74

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DX
HRMY
Founded
1987
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.2B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
DX
HRMY
Price
$9.93
$32.74
Analyst Decision
Buy
Buy
Analyst Count
6
12
Target Price
$12.60
★ $48.08
AVG Volume (30 Days)
★ 5.9M
1.0M
Earning Date
10-19-2026
11-04-2026
Dividend Yield
★ 20.71%
N/A
EPS Growth
★ 65.77
7.97
EPS
N/A
★ 2.63
Revenue
N/A
★ $868,453,000.00
Revenue This Year
$2.39
$18.31
Revenue Next Year
$41.18
$14.97
P/E Ratio
★ N/A
$12.53
Revenue Growth
N/A
★ 21.51
52 Week Low
$9.60
$25.90
52 Week High
$14.93
$43.49

Technical Indicators

Market Signals
Indicator
DX
HRMY
Relative Strength Index (RSI) 34.28 32.34
Support Level N/A $32.53
Resistance Level $11.17 $34.16
Average True Range (ATR) 0.30 1.44
MACD -0.05 -0.06
Stochastic Oscillator 19.59 4.78

Price Performance

Historical Comparison
DX
HRMY

About DX Dynex Capital Inc.

Dynex Capital Inc is a real estate investment trust (REIT) focused on delivering dividends supported by long term returns from investments in mortgage assets backed by U.S. housing and commercial real estate. The Company is internally managed and mainly invests in residential and commercial mortgage-backed securities (RMBS and CMBS), which are Agency securities guaranteed by U.S. government-sponsored enterprises (GSEs). It manages interest rate, prepayment, spread, liquidity, and counterparty risks and operates through one reportable segment investing in MBS funded with repurchase agreements and equity.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: